PMA device
PartoSure Test
Qiagen, Inc. · Placental Alpha Microglobulin-1 Immunoassay (QBB, Class III) · First FDA decision Apr 11, 2018, newest Oct 11, 2019Pregnancy, labor and postpartum hemorrhage
Last checked: Nov 20, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
2
PMA pathway
Device trials
3
Naming "PartoSure"
MAUDE reports
0
Brand "PartoSure", since 2015
PubMed studies
16
Mentioning "PartoSure"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing PartoSure Test
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 2 of 2 decisions filed under this name.
- PartoSure TestPMA supplement
P160052-S001 · Decided Oct 11, 2019 · 518 days after receipt · Normal 180 Day Track No User Fee
Device type: Placental alpha microglobulin-1 immunoassay (QBB) · Laboratory Medicine & Pathology
P160052 · Decided Apr 11, 2018 · 497 days after receipt
Device type: Placental alpha microglobulin-1 immunoassay (QBB) · Laboratory Medicine & Pathology
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
No Medicare coverage document has a title matching this device or device type. Many devices are paid under existing codes without one.
Clinical trials
Device studies on ClinicalTrials.gov that name "PartoSure", any status and sponsor, newest update first.
University Hospital, Strasbourg, FranceAcademic, hospital or other
NCT04374916 · 200 participants (planned) · Start Aug 11, 2020 · Primary completion Apr 4, 2025
Device: Premaquick®; PARTOSURE® · For: Threatened Preterm Labor; Preterm Delivery
Sites: Strasbourg, France
Ziekenhuis Oost-LimburgAcademic, hospital or other
NCT05742997 · 165 participants (planned) · Start Oct 1, 2021 · Primary completion Aug 31, 2023
Device: PartoSure; Fetal Fibronectine · For: Preterm Birth
Sites: Genk, Belgium
- Evaluation of Vaginal PAMG-1 Detection by PartoSure Test in Preterm Delivery Threat in Actual Clinical Situation: Randomized Controlled TrialPivotal-lookingCompleted
University Hospital, BrestAcademic, hospital or other
NCT03675061 · 128 participants · Start Dec 11, 2018 · Primary completion Feb 23, 2021
Device: PartoSure Test negative; PartoSure Test positive · For: Pregnancy Preterm
Sites: Brest, France
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "PartoSure", and for the whole product code for context.
This brand
0 reports: 0 malfunction, 0 injury, 0 death
Whole product code QBB
0 reports: 0 malfunction, 0 injury, 0 death
Newest reports for this brand
No MAUDE reports name this brand.
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
No recall in FDA's data is linked to these FDA numbers.
Published research
The most relevant PubMed records for "PartoSure"[tiab]. The summary above synthesizes these.
- A diagnostic profile on the PartoSure test.
Rouholamin S, Razavi M, Rezaeinejad M, et al. · Expert Rev Mol Diagn · 2020
- Evaluation of a novel placental alpha microglobulin-1 (PAMG-1) test to predict spontaneous preterm delivery.
Nikolova T, Bayev O, Nikolova N, et al. · J Perinat Med · 2014Evaluation Study, Research Support, Non-U.S. Gov't
- Combination of the placental alpha-1 microglobulin test and ultrasonic cervical length measurement to predict the time of preterm birth.
Konoplyannikov AG, Dikke GB, Karaganova EY · J Matern Fetal Neonatal Med · 2022Observational Study
- Three biomarker tests to help diagnose preterm labour: a systematic review and economic evaluation.
Varley-Campbell J, Mújica-Mota R, Coelho H, et al. · Health Technol Assess · 2019Research Support, Non-U.S. Gov't, Systematic Review
- Comparison of a novel test for placental alpha microglobulin-1 with fetal fibronectin and cervical length measurement for the prediction of imminent spontaneous preterm delivery in patients with threatened preterm labor.
Nikolova T, Bayev O, Nikolova N, et al. · J Perinat Med · 2015Comparative Study, Observational Study
- Outperformance of interleukin-6 over placental alpha microglobulin-1 in predicting preterm delivery in symptomatic women.
Roca-Prats A, Diaz-Martinez A, Albaladejo-Belmonte M, et al. · Am J Obstet Gynecol MFM · 2023Observational Study, Research Support, Non-U.S. Gov't
- Placental Alpha Macroglobulin-1 (PartoSure) Immunoassay to Assess the Risk of Spontaneous Preterm Birth.
Brown SR · Am Fam Physician · 2020
- The value of a vaginal sample for detecting PAMG-1 (Partosure®) in women with a threatened preterm delivery (the MAPOSURE Study): protocol for a multicenter prospective study.
Marie E, Ducarme G, Boivin M, et al. · BMC Pregnancy Childbirth · 2020
- Prediction of preterm birth using PAMG-1 test: a single centre experience - preliminary report.
Cnota W, Jagielska A, Janowska E, et al. · Ginekol Pol · 2022
- Placental alpha microglobulin-1 (PartoSure) test for the prediction of preterm birth: a systematic review and meta-analysis.
Pirjani R, Moini A, Almasi-Hashiani A, et al. · J Matern Fetal Neonatal Med · 2021Meta-Analysis, Systematic Review
- Placental α-microglobulin-1 in cervicovaginal fluid and cervical length to predict preterm birth by Thai women with symptoms of labor.
Chawanpaiboon S, Titapant V, Pooliam J · Asian Biomed (Res Rev News) · 2021
- Methods of detection and prevention of preterm labour and the PAMG-1 detection test: a review.
Dochez V, Ducarme G, Gueudry P, et al. · J Perinat Med · 2021Systematic Review
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.